Chemical inhibitors of AVEN can interfere with its function through various mechanisms implicating multiple signaling pathways. Staurosporine, an inhibitor of protein kinases, can disrupt kinase interactions that are essential for AVEN's function. By intervening in these interactions, Staurosporine impedes AVEN's ability to participate in cellular signaling processes. Similarly, the PI3K inhibitors LY294002 and Wortmannin can diminish the pro-survival signals AVEN utilizes, thus indirectly inhibiting its anti-apoptotic function. These inhibitors target the PI3K/Akt pathway, which plays a pivotal role in cell survival, and their action results in an attenuated pathway function, thereby undermining AVEN's role in this context. PD98059 and U0126, both targeting the MAPK pathway by inhibiting MEK, can also indirectly influence AVEN's activity. Since the MAPK pathway is involved in cell growth and survival, these inhibitors may reduce AVEN's capacity to exert its anti-apoptotic effects by dampening the signaling through this pathway.
Continuing with the modulation of cell signaling, SB203580 and SP600125 act on the MAPK pathway by inhibiting p38 and JNK, respectively. Given that AVEN is implicated in stress responses potentially mediated by these kinases, their inhibition can lead to a decrease in AVEN's anti-apoptotic function. Rapamycin, an mTOR inhibitor, disrupts a central regulator of cell growth, and its action could thus affect AVEN if it is involved in mTOR-related survival pathways. Nutlin-3, by disrupting p53 and MDM2 interaction, may alter the regulatory influence of p53 on AVEN. Bortezomib, a proteasome inhibitor, could alter the degradation rate of proteins that regulate AVEN, leading to an indirect suppression of its function. Z-VAD-FMK, although primarily a caspase inhibitor, could perturb AVEN's interactions within apoptosis pathways if these interactions are caspase-dependent. Lastly, Trichostatin A, by inhibiting histone deacetylases, alters gene expression patterns and could affect AVEN's role in cell survival, leading to a functional inhibition of AVEN within these altered cellular states.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can inhibit a broad range of protein kinases. If AVEN's function involves kinase interactions, this inhibitor could disrupt those interactions, leading to the functional inhibition of AVEN. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K signaling can influence cell survival pathways where AVEN is implicated, inhibition of PI3K could diminish AVEN's ability to inhibit apoptosis indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. By inhibiting PI3K, it could indirectly reduce the pro-survival signals that AVEN utilizes to exert its anti-apoptotic effects. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK pathway. If AVEN's anti-apoptotic function is ERK-dependent, MEK inhibition by PD98059 could indirectly impede AVEN's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If AVEN's function is modulated through the p38 MAPK stress response pathway, inhibition by SB203580 could decrease AVEN's anti-apoptotic function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. Since JNK is involved in stress responses, inhibiting JNK could disrupt pathways that may indirectly modulate AVEN's anti-apoptotic functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central cell growth regulator. By inhibiting mTOR, it could indirectly affect AVEN's function if AVEN is involved in mTOR signaling pathways linked to cell survival. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2. If AVEN is regulated by p53 activity, Nutlin-3 could indirectly inhibit AVEN by restoring p53 function and its regulatory effects. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it could increase the degradation of proteins involved in the regulation of AVEN, thereby indirectly inhibiting AVEN's function. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor. Although primarily known to prevent apoptosis, if AVEN's function depends on caspase activity, its inhibition might disturb AVEN's anti-apoptotic interactions. | ||||||